We are live on ! Find out more
CELZ icon

Creative Medical Technology

15 hedge funds and large institutions have $176K invested in Creative Medical Technology in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $157K → $176K (+$18.7K)

0.04% less ownership

Funds ownership: 0.29%0.25% (-0.04%)

17% less funds holding

Funds holding: 1815 (-3)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
15
Holders Change
-3
Holders Change %
-16.67%
% of All Funds
0.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
3
Reduced
Closed
6
Calls
Puts
Net Calls
Net Calls Change

CELZ Hedge Fund Activity: Q1 2023 in Review

15 of the 6,282 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q1 2023, worth a combined $176K — up 12% from $157K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CELZ and 3 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Geode Capital Management, adding an estimated $51K. The largest seller was Aaron Wealth Advisors, exiting entirely with an estimated $38.1K sold.

  • 15 institutional investors held Creative Medical Technology (CELZ) as of Q1 2023, down from 18 in Q4 2022.
  • Funds reported $176K of Creative Medical Technology stock for Q1 2023, up 12% quarter-over-quarter.
  • 3 funds opened new Creative Medical Technology positions in Q1 2023 and 6 closed out, a net change of -3 holders.
  • The largest Creative Medical Technology buyer in Q1 2023 was Geode Capital Management, an estimated $51K added.
  • The largest Creative Medical Technology seller in Q1 2023 was Aaron Wealth Advisors, an estimated $38.1K sold.

Based on aggregated 13F filings for Q1 2023.